Search global stocks & ETFs...Ctrl K
Learn Mode
BioMarin Pharmaceutical IncBMRN
$58.99
$1.17 (2.024%)
$58.71
-$0.28 (-0.475%)
BMRN
Stock Profile
08-03
Recommended Metric
Score Card
Explore Scores Tab
3.36
Average
Valuation Score
Key Score
5.00
Very Good
Management
5.00
Very Good
Growth
1.00
Very Bad
Profitability
1.00
Very Bad
Fin. Health
4.00
Good
Dividends
--
--
Analyst
1.00
Very Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$58.99
Baseline
High
$126.00
▲
113.60%
Avg
$92.68
▲
57.11%
Low
$55.55
▼
-5.83%
Analyst Ratings based on 34 Analysts
Strong Buy
1132%
Buy
1647%
Hold
721%
Sell
000%
Strong Sell
000%
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its Galafold (migalastat) is the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease.Read More